[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fVrUjjcBktFdjdR3e_hpBwpP7JlcfcfywXt9voECIo40":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":53,"rows":60},"iOMEDICO AG",[4],53,false,17,3,49747,6,34,[14,17,19,21,24,26,28,30],{"name":15,"count":16},"Breast Cancer",7,{"name":18,"count":16},"Multiple Myeloma",{"name":20,"count":9},"Renal Cell Carcinoma",{"name":22,"count":23},"Cholangiocarcinoma",2,{"name":25,"count":23},"Metastatic Breast Cancer",{"name":27,"count":23},"Hormone Receptor Positive Tumor",{"name":29,"count":23},"Chronic Lymphocytic Leukemia (CLL)",{"name":31,"count":23},"HER2-positive Breast Cancer",[33,38,43,48],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT05954780","Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma","2026-10-30","Selinexor",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT07563595","Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer","2028-05","Elacestrant",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT05326308","Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma","2028-08","Zanubrutinib",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT07240662","Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma","2031-11","Vorasidenib",[54,55,56,57,58,59],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[61,86,104,125,151,169,191,236,258,288,320,348,380,407,425,443,461,479,497,515,533,551,576,603,621,647,676,701,726,750],{"intervention":42,"totalTrials":62,"cells":63},1,{"EARLY_PHASE1":64,"PHASE1":67,"PHASE2":69,"PHASE3":71,"PHASE4":73,"NA":75},{"trials":65,"activeCount":66},[],0,{"trials":68,"activeCount":66},[],{"trials":70,"activeCount":66},[],{"trials":72,"activeCount":66},[],{"trials":74,"activeCount":66},[],{"trials":76,"activeCount":62,"soonestReadout":41},[77],{"nctId":39,"briefTitle":40,"status":78,"phases":79,"primaryCompletion":41,"completion":80,"start":81,"enrollment":82,"conditions":83,"interventions":84},"NOT_YET_RECRUITING",[],"2029-07","2026-05",500,[15],[42,85],"Standard of care",{"intervention":85,"totalTrials":62,"cells":87},{"EARLY_PHASE1":88,"PHASE1":90,"PHASE2":92,"PHASE3":94,"PHASE4":96,"NA":98},{"trials":89,"activeCount":66},[],{"trials":91,"activeCount":66},[],{"trials":93,"activeCount":66},[],{"trials":95,"activeCount":66},[],{"trials":97,"activeCount":66},[],{"trials":99,"activeCount":62,"soonestReadout":41},[100],{"nctId":39,"briefTitle":40,"status":78,"phases":101,"primaryCompletion":41,"completion":80,"start":81,"enrollment":82,"conditions":102,"interventions":103},[],[15],[42,85],{"intervention":37,"totalTrials":62,"cells":105},{"EARLY_PHASE1":106,"PHASE1":108,"PHASE2":110,"PHASE3":112,"PHASE4":114,"NA":116},{"trials":107,"activeCount":66},[],{"trials":109,"activeCount":66},[],{"trials":111,"activeCount":66},[],{"trials":113,"activeCount":66},[],{"trials":115,"activeCount":66},[],{"trials":117,"activeCount":62,"soonestReadout":36},[118],{"nctId":34,"briefTitle":35,"status":119,"phases":120,"primaryCompletion":36,"completion":36,"start":121,"enrollment":122,"conditions":123,"interventions":124},"ACTIVE_NOT_RECRUITING",[],"2023-06-28",75,[18],[37],{"intervention":47,"totalTrials":62,"cells":126},{"EARLY_PHASE1":127,"PHASE1":129,"PHASE2":131,"PHASE3":133,"PHASE4":135,"NA":137},{"trials":128,"activeCount":66},[],{"trials":130,"activeCount":66},[],{"trials":132,"activeCount":66},[],{"trials":134,"activeCount":66},[],{"trials":136,"activeCount":66},[],{"trials":138,"activeCount":62,"soonestReadout":46},[139],{"nctId":44,"briefTitle":45,"status":140,"phases":141,"primaryCompletion":46,"completion":46,"start":142,"enrollment":143,"conditions":144,"interventions":149},"RECRUITING",[],"2022-04-26",705,[145,146,147,148],"Waldenström's Macroglobulinemia","Chronic Lymphocytic Leukemia","Marginal Zone Lymphoma","Follicular Lymphoma",[47,150],"Obinutuzumab",{"intervention":150,"totalTrials":62,"cells":152},{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":161,"NA":163},{"trials":154,"activeCount":66},[],{"trials":156,"activeCount":66},[],{"trials":158,"activeCount":66},[],{"trials":160,"activeCount":66},[],{"trials":162,"activeCount":66},[],{"trials":164,"activeCount":62,"soonestReadout":46},[165],{"nctId":44,"briefTitle":45,"status":140,"phases":166,"primaryCompletion":46,"completion":46,"start":142,"enrollment":143,"conditions":167,"interventions":168},[],[145,146,147,148],[47,150],{"intervention":52,"totalTrials":62,"cells":170},{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":179,"NA":181},{"trials":172,"activeCount":66},[],{"trials":174,"activeCount":66},[],{"trials":176,"activeCount":66},[],{"trials":178,"activeCount":66},[],{"trials":180,"activeCount":66},[],{"trials":182,"activeCount":62,"soonestReadout":51},[183],{"nctId":49,"briefTitle":50,"status":140,"phases":184,"primaryCompletion":51,"completion":185,"start":186,"enrollment":187,"conditions":188,"interventions":190},[],"2032-01","2025-12-08",150,[189],"Glioma",[52],{"intervention":192,"totalTrials":23,"cells":193},"Bevacizumab",{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":200,"PHASE4":216,"NA":234},{"trials":195,"activeCount":66},[],{"trials":197,"activeCount":66},[],{"trials":199,"activeCount":66},[],{"trials":201,"activeCount":66},[202],{"nctId":203,"briefTitle":204,"status":205,"phases":206,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":212},"NCT00868634","Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer","COMPLETED",[57],"2014-03","2015-10","2009-02",600,[25],[213,214,213,214,215],"capecitabine","bevacizumab","vinorelbine",{"trials":217,"activeCount":66},[218],{"nctId":219,"briefTitle":220,"status":205,"phases":221,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":230},"NCT02248571","Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab",[58],"2017-08-31","2017-09-30","2014-08",85,[227,228,229],"Breast Cancer Recurrent","HER2\u002FNeu-negative Carcinoma of Breast","Hormone Receptor Positive Malignant Neoplasm of Breast",[192,231,232,233],"Capecitabine","Everolimus","Exemestane",{"trials":235,"activeCount":66},[],{"intervention":231,"totalTrials":23,"cells":237},{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":250,"NA":256},{"trials":239,"activeCount":66},[],{"trials":241,"activeCount":66},[],{"trials":243,"activeCount":66},[],{"trials":245,"activeCount":66},[246],{"nctId":203,"briefTitle":204,"status":205,"phases":247,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":248,"interventions":249},[57],[25],[213,214,213,214,215],{"trials":251,"activeCount":66},[252],{"nctId":219,"briefTitle":220,"status":205,"phases":253,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":254,"interventions":255},[58],[227,228,229],[192,231,232,233],{"trials":257,"activeCount":66},[],{"intervention":232,"totalTrials":23,"cells":259},{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":266,"PHASE4":268,"NA":286},{"trials":261,"activeCount":66},[],{"trials":263,"activeCount":66},[],{"trials":265,"activeCount":66},[],{"trials":267,"activeCount":66},[],{"trials":269,"activeCount":66},[270,274],{"nctId":219,"briefTitle":220,"status":205,"phases":271,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":272,"interventions":273},[58],[227,228,229],[192,231,232,233],{"nctId":275,"briefTitle":276,"status":205,"phases":277,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":285},"NCT01266837","Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)",[58],"2017-09-26","2017-10-31","2011-03",64,[283,284],"Metastatic Renal Cell Carcinoma","Failure of Exactly One Prior VEGF-targeted Therapy",[232],{"trials":287,"activeCount":66},[],{"intervention":233,"totalTrials":23,"cells":289},{"EARLY_PHASE1":290,"PHASE1":292,"PHASE2":294,"PHASE3":310,"PHASE4":312,"NA":318},{"trials":291,"activeCount":66},[],{"trials":293,"activeCount":66},[],{"trials":295,"activeCount":66},[296],{"nctId":297,"briefTitle":298,"status":205,"phases":299,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":305},"NCT02894398","Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant",[56],"2023-02-15","2016-09-06",388,[15,27,304],"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",[306,307,308,233,309],"Palbociclib","Letrozole","Anastrozole","Fulvestrant",{"trials":311,"activeCount":66},[],{"trials":313,"activeCount":66},[314],{"nctId":219,"briefTitle":220,"status":205,"phases":315,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":316,"interventions":317},[58],[227,228,229],[192,231,232,233],{"trials":319,"activeCount":66},[],{"intervention":321,"totalTrials":62,"cells":322},"Pazopanib",{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":346},{"trials":324,"activeCount":66},[],{"trials":326,"activeCount":66},[],{"trials":328,"activeCount":66},[],{"trials":330,"activeCount":66},[],{"trials":332,"activeCount":66},[333],{"nctId":334,"briefTitle":335,"status":205,"phases":336,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":345},"NCT01521715","First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma",[58],"2017-06-30","2017-07-31","2012-01-24",44,[342,343,344],"Locally Advanced and\u002For Metastatic Renal Cell Carcinoma","Carcinoma, Renal Cell","Clear-cell Metastatic Renal Cell Carcinoma",[321],{"trials":347,"activeCount":66},[],{"intervention":215,"totalTrials":23,"cells":349},{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":376,"NA":378},{"trials":351,"activeCount":66},[],{"trials":353,"activeCount":66},[],{"trials":355,"activeCount":66},[],{"trials":357,"activeCount":66},[358,362],{"nctId":203,"briefTitle":204,"status":205,"phases":359,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":360,"interventions":361},[57],[25],[213,214,213,214,215],{"nctId":363,"briefTitle":364,"status":365,"phases":366,"primaryCompletion":367,"completion":367,"start":368,"enrollment":66,"conditions":369,"interventions":371},"NCT03811418","A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer","WITHDRAWN",[57],"2019-04","2019-01",[370,31],"Advanced Breast Cancer",[372,373,374,375],"Trastuzumab","Pertuzumab","Vinorelbine","Docetaxel",{"trials":377,"activeCount":66},[],{"trials":379,"activeCount":66},[],{"intervention":381,"totalTrials":62,"cells":382},"Ribociclib and aromatase inhibitor or fulvestrant",{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":403,"NA":405},{"trials":384,"activeCount":66},[],{"trials":386,"activeCount":66},[],{"trials":388,"activeCount":66},[],{"trials":390,"activeCount":66},[391],{"nctId":392,"briefTitle":393,"status":205,"phases":394,"primaryCompletion":395,"completion":396,"start":397,"enrollment":398,"conditions":399,"interventions":401},"NCT03462251","Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line",[57],"2021-11-30","2022-11-30","2018-05-24",41,[15,27,400],"HER 2 Negative Breast Cancer",[381,402],"Capecitabine + bevacizumab OR Paclitaxel +\u002F- bevacizumab",{"trials":404,"activeCount":66},[],{"trials":406,"activeCount":66},[],{"intervention":402,"totalTrials":62,"cells":408},{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":415,"PHASE4":421,"NA":423},{"trials":410,"activeCount":66},[],{"trials":412,"activeCount":66},[],{"trials":414,"activeCount":66},[],{"trials":416,"activeCount":66},[417],{"nctId":392,"briefTitle":393,"status":205,"phases":418,"primaryCompletion":395,"completion":396,"start":397,"enrollment":398,"conditions":419,"interventions":420},[57],[15,27,400],[381,402],{"trials":422,"activeCount":66},[],{"trials":424,"activeCount":66},[],{"intervention":372,"totalTrials":62,"cells":426},{"EARLY_PHASE1":427,"PHASE1":429,"PHASE2":431,"PHASE3":433,"PHASE4":439,"NA":441},{"trials":428,"activeCount":66},[],{"trials":430,"activeCount":66},[],{"trials":432,"activeCount":66},[],{"trials":434,"activeCount":66},[435],{"nctId":363,"briefTitle":364,"status":365,"phases":436,"primaryCompletion":367,"completion":367,"start":368,"enrollment":66,"conditions":437,"interventions":438},[57],[370,31],[372,373,374,375],{"trials":440,"activeCount":66},[],{"trials":442,"activeCount":66},[],{"intervention":373,"totalTrials":62,"cells":444},{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":451,"PHASE4":457,"NA":459},{"trials":446,"activeCount":66},[],{"trials":448,"activeCount":66},[],{"trials":450,"activeCount":66},[],{"trials":452,"activeCount":66},[453],{"nctId":363,"briefTitle":364,"status":365,"phases":454,"primaryCompletion":367,"completion":367,"start":368,"enrollment":66,"conditions":455,"interventions":456},[57],[370,31],[372,373,374,375],{"trials":458,"activeCount":66},[],{"trials":460,"activeCount":66},[],{"intervention":375,"totalTrials":62,"cells":462},{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":469,"PHASE4":475,"NA":477},{"trials":464,"activeCount":66},[],{"trials":466,"activeCount":66},[],{"trials":468,"activeCount":66},[],{"trials":470,"activeCount":66},[471],{"nctId":363,"briefTitle":364,"status":365,"phases":472,"primaryCompletion":367,"completion":367,"start":368,"enrollment":66,"conditions":473,"interventions":474},[57],[370,31],[372,373,374,375],{"trials":476,"activeCount":66},[],{"trials":478,"activeCount":66},[],{"intervention":306,"totalTrials":62,"cells":480},{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":491,"PHASE4":493,"NA":495},{"trials":482,"activeCount":66},[],{"trials":484,"activeCount":66},[],{"trials":486,"activeCount":66},[487],{"nctId":297,"briefTitle":298,"status":205,"phases":488,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":489,"interventions":490},[56],[15,27,304],[306,307,308,233,309],{"trials":492,"activeCount":66},[],{"trials":494,"activeCount":66},[],{"trials":496,"activeCount":66},[],{"intervention":307,"totalTrials":62,"cells":498},{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":509,"PHASE4":511,"NA":513},{"trials":500,"activeCount":66},[],{"trials":502,"activeCount":66},[],{"trials":504,"activeCount":66},[505],{"nctId":297,"briefTitle":298,"status":205,"phases":506,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":507,"interventions":508},[56],[15,27,304],[306,307,308,233,309],{"trials":510,"activeCount":66},[],{"trials":512,"activeCount":66},[],{"trials":514,"activeCount":66},[],{"intervention":308,"totalTrials":62,"cells":516},{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":527,"PHASE4":529,"NA":531},{"trials":518,"activeCount":66},[],{"trials":520,"activeCount":66},[],{"trials":522,"activeCount":66},[523],{"nctId":297,"briefTitle":298,"status":205,"phases":524,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":525,"interventions":526},[56],[15,27,304],[306,307,308,233,309],{"trials":528,"activeCount":66},[],{"trials":530,"activeCount":66},[],{"trials":532,"activeCount":66},[],{"intervention":309,"totalTrials":62,"cells":534},{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":545,"PHASE4":547,"NA":549},{"trials":536,"activeCount":66},[],{"trials":538,"activeCount":66},[],{"trials":540,"activeCount":66},[541],{"nctId":297,"briefTitle":298,"status":205,"phases":542,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":543,"interventions":544},[56],[15,27,304],[306,307,308,233,309],{"trials":546,"activeCount":66},[],{"trials":548,"activeCount":66},[],{"trials":550,"activeCount":66},[],{"intervention":552,"totalTrials":62,"cells":553},"Ivosidenib",{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":564},{"trials":555,"activeCount":66},[],{"trials":557,"activeCount":66},[],{"trials":559,"activeCount":66},[],{"trials":561,"activeCount":66},[],{"trials":563,"activeCount":66},[],{"trials":565,"activeCount":66},[566],{"nctId":567,"briefTitle":568,"status":205,"phases":569,"primaryCompletion":570,"completion":570,"start":571,"enrollment":572,"conditions":573,"interventions":575},"NCT06181734","Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC",[],"2025-07-30","2023-12-20",8,[574],"Acute Myeloid Leukemia (AML)",[552],{"intervention":577,"totalTrials":62,"cells":578},"Nab-Paclitaxel",{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":583,"PHASE3":585,"PHASE4":587,"NA":589},{"trials":580,"activeCount":66},[],{"trials":582,"activeCount":66},[],{"trials":584,"activeCount":66},[],{"trials":586,"activeCount":66},[],{"trials":588,"activeCount":66},[],{"trials":590,"activeCount":66},[591],{"nctId":592,"briefTitle":593,"status":205,"phases":594,"primaryCompletion":595,"completion":596,"start":597,"enrollment":598,"conditions":599,"interventions":601},"NCT02799862","Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC",[],"2019-12-07","2021-06-06","2016-08-29",408,[600],"Carcinoma, Non-Small-Cell Lung",[577,602],"Carboplatin",{"intervention":602,"totalTrials":62,"cells":604},{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":611,"PHASE4":613,"NA":615},{"trials":606,"activeCount":66},[],{"trials":608,"activeCount":66},[],{"trials":610,"activeCount":66},[],{"trials":612,"activeCount":66},[],{"trials":614,"activeCount":66},[],{"trials":616,"activeCount":66},[617],{"nctId":592,"briefTitle":593,"status":205,"phases":618,"primaryCompletion":595,"completion":596,"start":597,"enrollment":598,"conditions":619,"interventions":620},[],[600],[577,602],{"intervention":622,"totalTrials":62,"cells":623},"Ripretinib",{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":630,"PHASE4":632,"NA":634},{"trials":625,"activeCount":66},[],{"trials":627,"activeCount":66},[],{"trials":629,"activeCount":66},[],{"trials":631,"activeCount":66},[],{"trials":633,"activeCount":66},[],{"trials":635,"activeCount":66},[636],{"nctId":637,"briefTitle":638,"status":205,"phases":639,"primaryCompletion":640,"completion":641,"start":642,"enrollment":643,"conditions":644,"interventions":646},"NCT06619275","Ripretinib (QINLOCK®) According to Current SmPC",[],"2025-08-15","2025-09-15","2024-10-17",10,[645],"GIST - Gastrointestinal Stromal Tumor",[622],{"intervention":648,"totalTrials":62,"cells":649},"Daratumumab",{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":656,"PHASE4":658,"NA":660},{"trials":651,"activeCount":66},[],{"trials":653,"activeCount":66},[],{"trials":655,"activeCount":66},[],{"trials":657,"activeCount":66},[],{"trials":659,"activeCount":66},[],{"trials":661,"activeCount":66},[662],{"nctId":663,"briefTitle":664,"status":205,"phases":665,"primaryCompletion":666,"completion":666,"start":667,"enrollment":668,"conditions":669,"interventions":675},"NCT05284591","Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)",[],"2024-09-20","2022-07-06",96,[18,670,671,672,673,674],"Newly Diagnosed","Transplant Ineligible","Patient Satisfaction","Patient Preference","Personal Satisfaction",[648],{"intervention":677,"totalTrials":62,"cells":678},"Carfilzomib",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":685,"PHASE4":687,"NA":689},{"trials":680,"activeCount":66},[],{"trials":682,"activeCount":66},[],{"trials":684,"activeCount":66},[],{"trials":686,"activeCount":66},[],{"trials":688,"activeCount":66},[],{"trials":690,"activeCount":66},[691],{"nctId":692,"briefTitle":693,"status":205,"phases":694,"primaryCompletion":695,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":700},"NCT02970747","Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients",[],"2025-04-26","2016-10-25",359,[699],"Multiple Myeloma in Relapse",[677],{"intervention":702,"totalTrials":62,"cells":703},"Calquence",{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":710,"PHASE4":712,"NA":714},{"trials":705,"activeCount":66},[],{"trials":707,"activeCount":66},[],{"trials":709,"activeCount":66},[],{"trials":711,"activeCount":66},[],{"trials":713,"activeCount":66},[],{"trials":715,"activeCount":66},[716],{"nctId":717,"briefTitle":718,"status":205,"phases":719,"primaryCompletion":720,"completion":720,"start":721,"enrollment":722,"conditions":723,"interventions":725},"NCT05517265","Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)",[],"2026-03-20","2022-10-12",45,[724],"CLL",[702,702],{"intervention":727,"totalTrials":62,"cells":728},"TUKYSA®",{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":733,"PHASE3":735,"PHASE4":737,"NA":739},{"trials":730,"activeCount":66},[],{"trials":732,"activeCount":66},[],{"trials":734,"activeCount":66},[],{"trials":736,"activeCount":66},[],{"trials":738,"activeCount":66},[],{"trials":740,"activeCount":66},[741],{"nctId":742,"briefTitle":743,"status":205,"phases":744,"primaryCompletion":745,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":749},"NCT05253911","Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.",[],"2025-06-30","2022-05-21",49,[31],[727],{"intervention":751,"totalTrials":62,"cells":752},"Panitumumab",{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":757,"PHASE3":759,"PHASE4":761,"NA":763},{"trials":754,"activeCount":66},[],{"trials":756,"activeCount":66},[],{"trials":758,"activeCount":66},[],{"trials":760,"activeCount":66},[],{"trials":762,"activeCount":66},[],{"trials":764,"activeCount":66},[765],{"nctId":766,"briefTitle":767,"status":205,"phases":768,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":772,"interventions":775},"NCT03043950","Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)",[],"2024-01-17","2017-01-25",647,[773,774],"Metastatic Colorectal Cancer","RAS Wild-type",[751]]